You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

75 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
Feb 2024
Drug
Other Name(s): Kyprolis®
Feb 2024
Guidelines and Advice
Jan 2016

Pages